Skip to main navigation
Lisata Therapeutics Caladrius
Lisata Therapeutics Caladrius
  • Careers
  • Contact Us
  • Policies
Active Clinical Trials
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Pancreatic Cancer & Advanced Solid Tumors LSTA1
    • Solid Tumors Tumor-Penetrating Nanocomplex (TPN) Platform™
    • Coronary Microvascular Dysfunction (CMD): XOWNA®
    • Critical Limb Ischemia (CLI) LSTA12 (HONEDRA® in Japan)
    • Diabetic Kidney Disease (DKD) LSTA201
    • No-Option Refractory Disabling Angina (NORDA) LSTA14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CendR Platform™ Technology
    • CD34+ Cell Technology
    • Publications
  • Investors & News
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
      • Media Coverage
    • Financials & Filings
      • Quarterly Results
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Docs & Charters
      • Management
      • Board of Directors
    • Historical Information
      • Historical Press Releases
      • Historical SEC Filings
    • Investor Resources
      • Stockholder Information
      • Investor FAQs
      • Email Alerts
      • IR Contact
      • Policies & Disclosures
  • Patients & Families
    • Overview
    • Metastatic Pancreatic Cancer Symptoms & Treatment
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia and Buerger’s Disease Symptoms & Treatment
Investors & News / Press Releases /

Press Releases

More news releases are coming soon.
  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
Displaying 31 - 25 of 25
  • Print Page
  • RSS Feeds
  • Email Alerts
Lisata Therapeutics Caladrius
Lisata Therapeutics Caladrius
Active Clinical Trials
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Pancreatic Cancer & Advanced Solid Tumors LSTA1
    • Solid Tumors Tumor-Penetrating Nanocomplex (TPN) Platform™
    • Coronary Microvascular Dysfunction (CMD): XOWNA®
    • Critical Limb Ischemia (CLI) LSTA12 (HONEDRA® in Japan)
    • Diabetic Kidney Disease (DKD) LSTA201
    • No-Option Refractory Disabling Angina (NORDA) LSTA14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CendR Platform™ Technology
    • CD34+ Cell Technology
    • Publications
  • Investors & News
    • Overview
    • News & Events
    • Financials & Filings
    • Stock Information
    • Corporate Governance
    • Historical Information
    • Investor Resources
  • Patients & Families
    • Overview
    • Metastatic Pancreatic Cancer Symptoms & Treatment
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia and Buerger’s Disease Symptoms & Treatment
  • Facebook
  • Twitter
  • LinkedIn
Join Our Email List

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100

© 2023 Lisata Therapeutics, Inc. All rights reserved.
  • Site Map
  • Privacy Policy

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100